Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition

Lakefront Biotherapeutics NV

31/03/2026 06:32

March 31 (Reuters) - Gilead Sciences Inc GILD.O:

ENTERS BINDING AGREEMENT WITH GILEAD ON OURO MEDICINES ACQUISITION

GALAPAGOS AND GILEAD ENTER INTO BINDING AGREEMENT TO COLLABORATE ON ADVANCING FIRST IN CLASS T CELL ENGAGER PROGRAM FOR AUTOIMMUNE DISEASES

TO FUND 50% OF $1.675 BILLION UPFRONT AND 50% OF MILESTONE PAYMENTS FOR OURO DEAL

MAY SPEND $500 MILLION INDEPENDENTLY, INCLUDING UP TO $150 MILLION FOR SHARE REPURCHASES OR DIVIDENDS

Source text: ID:nGNE5kcYXR

Further company coverage: GILD.O

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))